Kynam Capital Management, LP Biocryst Pharmaceuticals Inc Transaction History
Kynam Capital Management, LP
- $1.58 Billion
- Q4 2024
A detailed history of Kynam Capital Management, LP transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Kynam Capital Management, LP holds 9,085,368 shares of BCRX stock, worth $85 Million. This represents 4.33% of its overall portfolio holdings.
Number of Shares
9,085,368
Previous 9,085,368
-0.0%
Holding current value
$85 Million
Previous $69 Million
1.05%
% of portfolio
4.33%
Previous 5.66%
Shares
9 transactions
Others Institutions Holding BCRX
# of Institutions
277Shares Held
167MCall Options Held
728KPut Options Held
989K-
Vanguard Group Inc Valley Forge, PA21.9MShares$205 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$187 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$111 Million1.3% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY8.14MShares$76.2 Million1.52% of portfolio
-
State Street Corp Boston, MA7.5MShares$70.2 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.74B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...